RecruitingPhase 3NCT06549595

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Studying Follicular lymphoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Principal Investigator: Chan Cheah, MBBS FRACP FRCPA DMSc
Sir Charles Gairdner Hospital (SCGH)
Intervention: Surovatamig(drug)
Enrollment: 1018 target
Eligibility: 18-130 years · All sexes
Timeline: 2024 – 2031

Study locations (30)

Research Site, Anchorage, Alaska, United States
Research Site, Aurora, Colorado, United States
Research Site, New Haven, Connecticut, United States
Research Site, Ann Arbor, Michigan, United States
Research Site, New York, New York, United States
Research Site, Nashville, Tennessee, United States
Research Site, Garran, Australia
Research Site, Heidelberg, Australia
Research Site, Macquarie University, Australia
Research Site, Nedlands, Australia
Research Site, Brussels, Belgium
Research Site, Ghent, Belgium
Research Site, Mechelen, Belgium
Research Site, Porto Alegre, Brazil
Research Site, São Paulo, Brazil
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06549595 on ClinicalTrials.gov

Other trials for Follicular lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Follicular lymphoma →

← Back to all trials